Source: CureToday articles
Dr. Cathy Eng discusses data that led to the FDA approval of Braftovi and Erbitux plus chemo for metastatic colorectal cancer with a BRAF V600E mutation.
Recent Content
- Investigational CAR T-Cell Therapy BCB-276 Receives Breakthrough Designation for Pediatric Patients Wirh DIPG
- Statins May Improve Survival in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib
- Asembia AXS25: Digital Pharmacy Strategies for Patient-Centered Care
- Fighting for Patients, Processes and Education
- Immune Therapy Expands Melanoma Treatment to More Patients
- The Importance of Personalized Treatment Approaches for Urologic Cancers
- Nurse’s Big Personality Makes Cancer Treatment More Bearable.
- Constraint-Induced Cognitive Therapy Found to Improve Multiple Long COVID Symptoms
- Givinostat Wins U.S. FDA Fast Track Designation for Patients With PV
- Expert: Understanding OTC Allergy Medications and Symptom Management